The power of deep learning to ligand-based novel drug discovery
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Deep discriminative and generative neural-network models are becoming an integral part of the modern approach to ligand-based novel drug discovery. The variety of different architectures of neural networks, the methods of their training, and the procedures of generating new molecules require expert knowledge to choose the most suitable approach. AREAS COVERED: Three different approaches to deep learning use in ligand-based drug discovery are considered: virtual screening, neural generative models, and mutation-based structure generation. Several architectures of neural networks for building either discriminative or generative models are considered in this paper, including deep multilayer neural networks, different kinds of convolutional neural networks, recurrent neural networks, and several types of autoencoders. Several kinds of learning frameworks are also considered, including adversarial learning and reinforcement learning. Different types of representations for generating molecules, including SMILES, graphs, and several alternative string representations are also considered. EXPERT OPINION: Two kinds of problem should be solved in order to make the models built using deep neural networks, especially generative models, a valuable option in ligand-based drug discovery: the issue of interpretability and explainability of deep-learning models and the issue of synthetic accessibility of novel compounds designed by deep-learning algorithms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochreiter, S., & Schmidhuber, J. (1997) · Neural Computation · doi:10.1162/neco.1997.9.8.1735 · Cited by 102,318
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
Weininger, D. (1988) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00057a005 · Cited by 7,436 · cited 1×
“1D-CNNs use SMILES [38] as a ‘ raw ’ representation and ‘ one-hot ’ encoding of a character in each position of the string as initial local descriptors.”
MethodCaruana, R. (1997) · Machine Learning · doi:10.1023/a:1007379606734 · Cited by 6,636
Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules
Gómez-Bombarelli, R., Wei, J. N., Duvenaud, D., Hernández-Lobato, J. M., Sánchez-Lengeling, B., Sheberla, D., Aguilera-Iparraguirre, J., Hirzel, T. D., Adams, R. P., & Aspuru-Guzik, A. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00572 · Cited by 3,106
Convolutional Networks on Graphs for Learning Molecular Fingerprints
Duvenaud, D., Maclaurin, D., Aguilera-Iparraguirre, J., Gómez-Bombarelli, R., Hirzel, T., Aspuru-Guzik, A., & Adams, R. P. (2015) · arXiv · doi:10.48550/arxiv.1509.09292 · Cited by 2,628
Planning chemical syntheses with deep neural networks and symbolic AI
Segler, M. H. S., Preuss, M., & Waller, M. P. (2018) · Nature · doi:10.1038/nature25978 · Cited by 1,847
The rise of deep learning in drug discovery
Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.039 · Cited by 1,770
Molecular graph convolutions: moving beyond fingerprints
Kearnes, S., McCloskey, K., Berndl, M., Pande, V., & Riley, P. (2016) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-016-9938-8 · Cited by 1,631
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573 · cited 1×
“Zhavoronkov et al. used VAE with a rich prior distribution in the latent space in combination with tensor decomposition and RL based on reward functions approximated by self-organizing maps (SOMs) to discover novel potent inhibitors of discoidin domain receptor 1 in 21 days [74], see Figure 5.”
Method
Cited by
Bai, Q., Liu, S., Tian, Y., Xu, T., Banegas‐Luna, A. J., Pérez‐Sánchez, H., Huang, J., Liu, H., & Yao, X. (2022) · WIREs Computational Molecular Science · doi:10.1002/wcms.1581 · Cited by 156
“79 First of all, the deep learning generative model is trained for producing the new molecular SMILES library.”
MethodVerkhivker, G. M., Agajanian, S., Hu, G., & Tao, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00136 · Cited by 76
Success stories of AI in drug discovery - where do things stand?
Mak, K.-K., Balijepalli, M. K., & Pichika, M. R. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.1985108 · Cited by 51
Metadata
- Authors
- Baskin, I. I.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2020-03-31
- Volume
- 15
- Issue
- 7
- Pages
- 755-764
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W3013169228
- Cited by
- 76
- References
- 27
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The power of deep learning to ligand-based novel drug discovery. https://app.cochat.ai/papers/10.1080/17460441.2020.1745183
- The paper
- Baskin, I. I. (2020). The power of deep learning to ligand-based novel drug discovery. Expert Opinion on Drug Discovery. https://doi.org/10.1080/17460441.2020.1745183
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.